Brief: Alphamab Oncology Says Unit, Tracon Pharmaceuticals And 3D Medicines (Beijing) Entered Into Agreement
20/12/2019 13:25
Dec 20 (Reuters) - Alphamab Oncology 9966.HK :
* UNIT, TRACON PHARMACEUTICALS AND 3D MEDICINES (BEIJING)
ENTERED
IN TO A COLLABORATIVE PARTNERSHIP AGREEMENT
* UNDER DEAL, TRACON IS RESPONSIBLE FOR AMONG OTHER THINGS,
DEVELOP AND COMMERCIALIZE KN035
* 3DMED & UNIT ENTITLED TO RECEIVE ROYALTY FEE FROM TRACON
AT
AMOUNT OF TEENS TO MID-DOUBLE DIGITS PERCENT OF RELEVANT NET
SALES OF KN035
Source text for Eikon: ID:nHKS3ZWkPp
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)